News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Almac Group Expands UK Commercial Capacity With the Acquisition of New Blistering Technology


10/3/2012 7:00:49 AM

October 03, 2012 -- Almac, a leading provider of contract services to the global Pharmaceutical and Biotech industries, is pleased to announce that it has expanded its MHRA/FDA approved UK commercial packaging facility with the acquisition of a state-of-the-art Noack N 623 blister packaging line from Romaco.

The acquisition comes in response to growing client demand for enhanced flexibility related to larger blister sizes and innovative multi unit blister formats, coupled to a requirement for non permeability and enhanced environmental protection, particularly product humidity control.

This highly flexible, cGMP compliant technology can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm. With its automatic feeding system, filling inspection and ejection station and shorter set-up times, the line provides increased productivity, processing over 25,000 blisters per hour, including multi-product blisters.

“Blister size and dosage formats are becoming increasingly more complex. Additionally, product handling for innovative new molecules often requires enhanced environmental controls. This investment allows Almac, through its Pharma Services business unit, to offer this additional flexibility,” says Geoff Sloan VP of Manufacturing Operations. “Through this acquisition, coupled with our immanent entry into the US commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs.”

“The blister technology from Romaco Noack offers high OEE values and low lifecycle costs. Product changeovers are carried out easily and cleaning is quickly done. Our machines prove themselves flexible in operation and versatile in use.”, says Bernd Webel, Sales Director, Romaco.

For more information on Almac’s commercial packaging capabilities, visit http://www.almacgroup.com/commercial-services

Almac will be exhibiting at CPHI Madrid, 9th – 11th October 2012 (booth number 10E41) and AAPS Chicago, 14th – 18th October 2012 (booth number 3027).

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

Tristan Jervis

Managing Partner

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP

Telephone: +44 (0)207 861 3838

Direct: +44 (0)207 861 3019

Fax: +44 (0)207 861 3839

E-mail: t.jervis@defacto.com

www.defacto.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES